<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=489233&amp;fmt=gif">

Electronic Signature


What is an Electronic Signature?

In the rapidly evolving pharmaceutical industry, maintaining data integrity, security, and compliance is critical. A useful tool in this regard is the electronic signature. In a well-regulated pharmaceutical industry, good record-keeping and operations are essential to maintain compliance, ensure efficiency, and ensure data integrity. In such cases, electronic signatures have become important tools that provide a secure and reliable way to sign electronic documents.

Electronic signature (e-signature) means a signature or signature made, received, or legally authorized by the signature of a person. This may be a signed electronic data transmission, such as a telephone transmission, or it may be an encrypted message. It works as a legal and security alternative to traditional written signatures, making documents useful and effective in the pharmaceutical industry.

According to the ethics of the pharmaceutical industry, information must conform to the principles of Attributable, Readable, Contemporary, Original, and Accurate – in short, ALCOA. In the case of an electronic signature, the user must "log in" by entering the username and password. If they are going to change size. In this way, we satisfy the 'Attributable principle'. The change is then permanently stored in an audit trail database with a timestamp and the value information. In this way, we satisfy the 'Attributable principle'. The change is then permanently stored in an audit trail database with a timestamp and the value information.



In 1976, Whitfield Diffie and Martin Hellman introduced the concept of public-key cryptography, which formed the basis for secure digital signatures. Their groundbreaking work laid the foundation for modern encryption techniques. The use of electronic signatures in the pharmaceutical industry has gained prominence over the years as technology has advanced and regulations have evolved. In the late 20th century, with the increasing use of computers and the internet, digital signatures started to gain recognition as a secure method of verifying the authenticity of electronic documents. Digital signatures use cryptographic techniques to ensure data integrity and authentication. 

In the early 2000s, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) began to address the use of electronic signatures in the pharmaceutical industry. FDA Electronic Records and Signatures Rule, In the United States, the FDA introduced 21 CFR Part 11, also known as the Electronic Records and Signatures Rule, in 2002. EU Guidelines for Electronic Records and Signatures, In the European Union, the EMA issued Annex 11 to its EudraLex Volume 4 guidelines in 2011. Over the years, both the FDA and the EMA have continued to update and refine their regulations related to electronic signatures and records. These updates reflect advancements in technology and address emerging challenges and concerns. 


Electronic Signature over the Paper-based Signature 

Electronic signatures have many advantages over traditional paper signatures. Electronic signatures eliminate the need to physically print, sign, and deliver documents. This saves time and resources by increasing data processing efficiency and reducing the amount of work involved in the paper process. Electronic signature solutions provide effective security measures, including user authentication, encryption, and authentication methods. These features ensure the authenticity and integrity of signature data by preventing unauthorized access, tampering, or fraud. Electronic signatures allow participants to sign and review documents anytime, anywhere. Ultimately, this leads to the integration of partners, contract partners, and regulators regardless of their physical location. Electronic signatures also help comply with regulations such as 21 CFR Part 11 (FDA) and EudraLex Annex 11 (EMA). In addition, the adoption of electronic signatures in the pharmaceutical industry reduces the costs associated with paper, printing, storage, and processing of physical records.


Regulatory Compliances of Electronic Signature 

The pharmaceutical industry operates under stringent regulatory frameworks, requiring accurate documentation and adherence to specific standards. Electronic signatures, when implemented correctly, can help ensure compliance with regulatory requirements such as 21 CFR Part 11 in the United States and EudraLex Annex 11 in the European Union.

Electronic signature solutions provide robust security measures, including user authentication, encryption, and audit trails. These features enable the verification of signatories, prevent unauthorized access, and maintain a comprehensive record of document history, contributing to data integrity and compliance. Furthermore, electronic signature platforms often offer additional features such as version control, automated reminders, and document tracking, further enhancing compliance management.


Applications of Electronic Signature in Pharma:


1. Regulatory Submissions

Pharmaceutical companies are required to submit various documents to regulatory agencies for approval, including clinical trial protocols, drug registration applications, and safety reports. Electronic signatures are used to sign and authenticate these submissions, ensuring compliance with regulatory requirements and streamlining the approval process.

2. Document Control and Quality Management

In pharmaceutical manufacturing, maintaining accurate and controlled documents is crucial for quality management and regulatory compliance. Electronic signatures are utilized in document control systems to sign and approve Standard Operating Procedures (SOPs), batch records, validation documents, and other critical documents. This ensures traceability, data integrity, and compliance with Good Manufacturing Practices (GMP).

3. Investigator Site File (ISF) Management

Clinical trials in the pharmaceutical industry involve extensive documentation at investigator sites. Electronic signatures are employed to sign and authenticate documents such as informed consent forms, case report forms, and study protocols in the Investigator Site File. This enables efficient management of study documentation and compliance with regulatory requirements.

4. Batch Record Review and Release

In pharmaceutical manufacturing, batch records document the steps and controls involved in the production of each batch of drug products. Electronic signatures play a crucial role in the review and release process of batch records, verifying that all required checks and approvals have been completed.


Electronic signatures have many advantages over paper signatures in the pharmaceutical industry, such as improved efficiency, enhanced security, compliance, reduced costs, direct information, fairness, and environmental security. By using electronic signature solutions, pharmaceutical companies can streamline processes, ensure data integrity, and meet the demands of a digitally enabled world.

If you found useful this description maybe you'll like to see:

We can make better science, together

Contact us to learn how we can help you make life-changing solutions.